A Double-blind Study of the Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration

Trial Profile

A Double-blind Study of the Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Insulin (Primary) ; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top